NCT05141656Unknown不适用
Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 20,000
- 试验地点
- 1
- 主要终点
- OS
研究概览
简要总结
This study is a multi-center observational study. The start time for data collection is August 31, 2019. Patients who have been treated at our institution from August 31, 2019, who were diagnosed with pancreatic tumors on or before August 31, 2019 (diagnosed in our hospital or outside hospitals) would all meet the inclusion conditions of the study and be considered enrollment. Patients' baseline and treatment data will be collected under informed concent. The combination of medical big data governance and the leading technology of the big data platform uses real world data to improve the quality and efficiency of pancreatic tumor diagnosis, treatment and scientific research.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18, both male and female;
- •Patients with primary pancreatic tumor diagnosed by histology, cytology or imaging;
- •Clinical or pathological staging is locally advanced or metastatic pancreatic tumor (newly diagnosed or after surgery and other treatments);
- •You can accept or have not received surgery, chemotherapy, radiotherapy, local treatment or traditional Chinese medicine for tumors;
- •The subject voluntarily joined the study and signed an informed consent form voluntarily.
排除标准
- •Pancreatic tumors are evaluated as metastatic lesions, not primary tumors of the pancreas.
结局指标
主要结局
OS
时间窗: 5 years
overall survival
次要结局
- PFS(5 years)
- DFS(5 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
To Improve the Ability of Early Screening and Diagnosis in Patients With Diabetic NephropathyDiabetic Kidney DiseaseNCT05047471Yiming Mu10,000
终止
不适用
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg TreatmentBreast CancerNCT01425294AstraZeneca231
撤回
3 期
To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.Breast CancerNCT03658213AstraZeneca
已完成
2 期
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With AchondroplasiaAchondroplasiaNCT05246033Visen Pharmaceuticals (Shanghai) Co., Ltd.24
Enrolling By Invitation
2 期
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)cGvHDNCT06186804Abbisko Therapeutics Co, Ltd64